VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss

Cancer Biology and Therapy

Volumn 6, Issue 9, 2007, Pages 1449-1454

  Bowen, Joanne M ^a   Stringer, Andrea M ^a,b   Gibson, Rachel J ^a,b   Yeoh, Ann S J ^a,b   Hannam, Sarah ^b   Keefe, Dorothy M K ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Apoptosis; Chemotherapy; Diarrhea; Intestine; Mucositis; Probiotic

Indexed keywords

IRINOTECAN; MUCIN; PROBIOTIC AGENT; VSL3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DIARRHEA; FEMALE; GOBLET CELL; INTESTINE CRYPT; JEJUNUM; MUCOSA INFLAMMATION; NONHUMAN; RAT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DIARRHEA; FEMALE; GOBLET CELLS; HUMANS; IN SITU NICK-END LABELING; MUCINS; MUCOSITIS; NEOPLASMS; ORGAN SIZE; PROBIOTICS; RATS; TREATMENT OUTCOME;

EID: 42549126844     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C, Famularo G. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002; 97:2150-2.
2. Delia P, Sansotta G, Donato V, Messina G, Frosina P, Pergolizzi S, De Renzis C. Prophylaxis of diarrhea in patients submitted to radiotherapeutic treatment on pelvic district: Personal experience. Dig Liver Dis 2002; 34:S84-6.
3. Stringer AM, Gibson RJ, Bowen JM, Logan RM, Yeoh ASJ, Keefe DMK. Chemotherapy-induced mucositis: The role of gastrointestinal microflora and mucins in the luminal environment. J Support Oncol 2007, (Accepted 20th October 2006).
4. Gibson RJ, Keefe DM. Cancer chemotherapy-induced diarrhea and constipation: Mechanisms of damage and prevention strategies. Support Care Cancer 2006; 14:890-900.
5. Sandle G, Perry M, Mathialahan T, Linley J, Robinson P, Hunter M, Maclennan K. Altered cryptal expression of luminal potassium (BK) channels in ulcerative colitis. J Pathol 2007; 212:66-73.
6. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Burns J, Keefe DM. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 2007; 232:96-106.
7. Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 2003; 14:805-6.
8. Alimonti A, Gelibter A, Pavese I, Satta F, Cognetti F, Ferretti G, Rasio D, Vecchione A, Di Palma M. New approaches to prevent intestinal toxicity of irinotecan-based regimens. Cancer Treat Rev 2004; 30:555-62.
9. Gibson RJ, Bowen JM, Inglis MR, Cummins AG, Keefe DM. Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer. J Gastroenterol Hepatol 2003; 18:1095-100.
10. Leiper K, Campbell BJ, Jenkinson MD, Milton J, Yu LG, Democratis J, Rhodes JM. Interaction between bacterial peptides, neutrophils and goblet cells: A possible mechanism for neutrophil recruitment and goblet cell depletion in colitis. Clin Sci (Lond) 2001; 101:395-402.
11. Reid G, Hammond JA. Probiotics: Some evidence of their effectiveness. Can Fam Physician 2005; 51:1487-93.
12. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121:580-91.
13. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, Chang EB. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 2004; 127:1474-87.
14. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277-84.
15. Gibson RJ, Bowen JM, Keefe DM. Palifermin reduces diarrhea and increases survival following irinotecan treatment in tumor-bearing DA rats. Int J Cancer 2005; 116:464-70.
16. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119:493-501.
17. Gibson RJ, Bowen JB, Alvares A, Finnie J, Keefe DMK. Establishment of a single-dose irinotecan model of gastrointestinal mucositis. Chemotherapy 2007, In press.
18. Linsalata M, Russo F, Berloco P, Valentini AM, Caruso ML, De Simone C, Barone M, Polimeno L, Di Leo A. Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats. In Vivo 2005; 19:989-95.
19. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002; 277:50959-65.
20. Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2007; 43:395-401
21. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB. Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 2004; 100:1995-2025.
22. Sonis ST. A biological approach to mucositis. J Support Oncol 2004; 2:21-32, (discussion 5-6).